Prescient Therapeutics Management
Management criteria checks 3/4
Prescient Therapeutics' CEO is Steven Yatomi-Clarke, appointed in Feb 2016, has a tenure of 8.08 years. total yearly compensation is A$663.24K, comprised of 60.3% salary and 39.7% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth A$559.75K. The average tenure of the management team and the board of directors is 8.1 years and 8.8 years respectively.
Key information
Steven Yatomi-Clarke
Chief executive officer
AU$663.2k
Total compensation
CEO salary percentage | 60.3% |
CEO tenure | 8.1yrs |
CEO ownership | 1.4% |
Management average tenure | 8.1yrs |
Board average tenure | 8.8yrs |
Recent management updates
Recent updates
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -AU$8m |
Sep 30 2023 | n/a | n/a | -AU$7m |
Jun 30 2023 | AU$663k | AU$400k | -AU$7m |
Mar 31 2023 | n/a | n/a | -AU$6m |
Dec 31 2022 | n/a | n/a | -AU$5m |
Sep 30 2022 | n/a | n/a | -AU$5m |
Jun 30 2022 | AU$771k | AU$392k | -AU$5m |
Mar 31 2022 | n/a | n/a | -AU$5m |
Dec 31 2021 | n/a | n/a | -AU$5m |
Sep 30 2021 | n/a | n/a | -AU$5m |
Jun 30 2021 | AU$800k | AU$360k | -AU$4m |
Mar 31 2021 | n/a | n/a | -AU$4m |
Dec 31 2020 | n/a | n/a | -AU$3m |
Sep 30 2020 | n/a | n/a | -AU$3m |
Jun 30 2020 | AU$639k | AU$392k | -AU$3m |
Mar 31 2020 | n/a | n/a | -AU$4m |
Dec 31 2019 | n/a | n/a | -AU$4m |
Sep 30 2019 | n/a | n/a | -AU$4m |
Jun 30 2019 | AU$586k | AU$367k | -AU$4m |
Mar 31 2019 | n/a | n/a | -AU$3m |
Dec 31 2018 | n/a | n/a | -AU$3m |
Sep 30 2018 | n/a | n/a | -AU$3m |
Jun 30 2018 | AU$479k | AU$330k | -AU$3m |
Mar 31 2018 | n/a | n/a | -AU$3m |
Dec 31 2017 | n/a | n/a | -AU$3m |
Sep 30 2017 | n/a | n/a | -AU$3m |
Jun 30 2017 | AU$502k | AU$316k | -AU$3m |
Compensation vs Market: Steven's total compensation ($USD431.96K) is above average for companies of similar size in the Australian market ($USD295.21K).
Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.
CEO
Steven Yatomi-Clarke
8.1yrs
Tenure
AU$663,236
Compensation
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD, CEO & Director | 8.1yrs | AU$663.24k | 1.39% A$ 559.7k | |
CFO & Company Secretary | 9.1yrs | AU$158.40k | no data | |
Director of Clinical Affairs & Operations | 3.2yrs | no data | no data | |
Chief Medical Officer | 8.9yrs | AU$157.36k | no data | |
Senior Vice President of Scientific Affairs | 2.2yrs | no data | no data |
8.1yrs
Average Tenure
Experienced Management: PTX's management team is seasoned and experienced (8.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD, CEO & Director | 9.3yrs | AU$663.24k | 1.39% A$ 559.7k | |
Independent Non-Executive Chairman | 9.8yrs | AU$106.05k | 0.027% A$ 11.0k | |
Independent Non-Executive Director | 9.3yrs | AU$65.26k | 0.049% A$ 19.8k | |
Chairman of Clinical Advisory Board | 12.8yrs | no data | no data | |
Member of Clinical Advisory Board | 12.8yrs | no data | no data | |
Member of Scientific Advisory Board | 9.5yrs | no data | no data | |
Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
Non-Executive Director | 3.8yrs | AU$65.26k | no data | |
Member of Scientific Advisory Board | 3.6yrs | no data | no data |
8.8yrs
Average Tenure
Experienced Board: PTX's board of directors are considered experienced (8.8 years average tenure).